Citigroup
PRAX icon

Citigroup’s Praxis Precision Medicines PRAX Stock Holding History

Citigroup’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.06M Buy
+10,500
New +$3.47M ﹤0.01% 2486
2025
Q2 		– Sell
-10,200
Closed -$386K – 5845
2025
Q1 		$386K Sell
10,200
-66,300
-87% -$4.14M ﹤0.01% 3812
2024
Q4 		$5.89M Buy
76,500
+600
+0.8% +$43.4K ﹤0.01% 1793
2024
Q3 		$4.37M Buy
+75,900
New +$4.1M ﹤0.01% 1967

Other funds holding PRAX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Citigroup's PRAX Position: Q3 2026 in Review

Citigroup increased its Praxis Precision Medicines (PRAX) stake by 59% in Q3 2026, buying an estimated $4.58M and bringing the position to 37,428 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1560.

Citigroup first reported a position in PRAX in Q4 2020 and has held it in 24 quarters since. 86 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • Citigroup held 37,428 shares of Praxis Precision Medicines worth $10.9M as of Q3 2026.
  • Citigroup bought 13,829 Praxis Precision Medicines shares in Q3 2026, an estimated $4.58M.
  • Praxis Precision Medicines made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1560 holding.
  • Citigroup first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 24 quarters since.
  • 86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.